<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515734</url>
  </required_header>
  <id_info>
    <org_study_id>JACCRO CC-13</org_study_id>
    <nct_id>NCT02515734</nct_id>
  </id_info>
  <brief_title>A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab</brief_title>
  <acronym>DEEPER</acronym>
  <official_title>A Randomized Phase II Study to Investigate the Deepness of Response of FOLFOXIRI Plus Cetuximab (Erbitux) Versus FOLFOXIRI Plus Bevacizumab as the First-line Therapy in Metastatic Colorectal Cancer Patients With RAS Wild-type Tumors: DEEPER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Clinical Cancer Research Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Clinical Cancer Research Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus&#xD;
      bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS&#xD;
      wild-type tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus&#xD;
      bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS&#xD;
      wild-type tumors. In this study the investigators employed deepness of response as a primary&#xD;
      endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best deepness of response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The maximum tumor shrinkage rates by Response Evaluation Criteria in Solid Tumors (RECIST) throughout the treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early tumor shrinkage</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>The rates of tumor shrinkage by RECIST at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deepness of response</measure>
    <time_frame>at 4 months</time_frame>
    <description>The tumor shrinkage rates by RECIST at 4 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of curatively resected metastatic lesion</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOXIRI+Bmab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the FOLFOXIRI + Bmab group receive until 12 cycles of FOLFOXIRI plus bevacizumab, consisting of a 30-minute infusion of bevacizumab at a dose of 5 mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and bevacizumab every 14 days until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOXIRI+Cmab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental group received until 12 cycles of FOLFOXIRI plus cetuximab, consisting of a 30-minute infusion of cetuximab first time at a dose of 400 mg per kilogram, after the second time at a dose of 250mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and cetuximab every 14 days until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>FOLFOXIRI+Bmab</arm_group_label>
    <arm_group_label>FOLFOXIRI+Cmab</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>FOLFOXIRI+Bmab</arm_group_label>
    <arm_group_label>FOLFOXIRI+Cmab</arm_group_label>
    <other_name>Levofolinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
    <arm_group_label>FOLFOXIRI+Bmab</arm_group_label>
    <arm_group_label>FOLFOXIRI+Cmab</arm_group_label>
    <other_name>CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>FOLFOXIRI+Bmab</arm_group_label>
    <arm_group_label>FOLFOXIRI+Cmab</arm_group_label>
    <other_name>eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>FOLFOXIRI+Bmab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <arm_group_label>FOLFOXIRI+Cmab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed colorectal cancer&#xD;
&#xD;
          -  RAS wild-type&#xD;
&#xD;
          -  Measurable lesion by RECIST (Ver.1.1)&#xD;
&#xD;
          -  No past history of chemotherapy in the case of unresectable primary lesion/distant&#xD;
             metastasis/lymph node metastasis.In the case of recurrence, no treatment for the first&#xD;
             recurrence lesion after operation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-1.The case &gt;=71 years&#xD;
             is PS0.&#xD;
&#xD;
          -  Life expectancy of more than 6 months&#xD;
&#xD;
          -  Patients have enough organ function for study treatment within 14 days before&#xD;
             enrollment;&#xD;
&#xD;
               1. White blood cell (WBC)&gt;=3,000/mm3, &lt;12,000/mm3.&#xD;
&#xD;
               2. Neu&gt;=1,500/mm3.&#xD;
&#xD;
               3. Platelet count (PLT) &gt;=10.0x104/mm3.&#xD;
&#xD;
               4. Hb&gt;=9.0g/dL.&#xD;
&#xD;
               5. Total Bilirubin&lt;=1.5x Upper Limited Normal (ULN)&#xD;
&#xD;
               6. aspartate aminotransferase (AST) &lt;=2.5xULN.&#xD;
&#xD;
               7. alanine aminotransferase (ALT) &lt;=2.5xULN.&#xD;
&#xD;
               8. Creatinine&lt;=1.5xULN.&#xD;
&#xD;
               9. Proteinuria&lt;=1+.&#xD;
&#xD;
              10. prothrombin time-international normalized ratio (PT-INR) &lt;=1.5&#xD;
&#xD;
          -  Must be able to swallow tablets&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Synchronous multiple malignancy or metachronous multiple malignancy within 5 years&#xD;
             disease free interval&#xD;
&#xD;
          -  Lynch syndrome&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Infectious disease&#xD;
&#xD;
          -  Interstitial lung disease or pulmonary fibrosis&#xD;
&#xD;
          -  Comorbidity or history of serious heart failure&#xD;
&#xD;
          -  History of thromboembolic events&#xD;
&#xD;
          -  Cerebrovascular disease&#xD;
&#xD;
          -  History of hemoptysis/hematemesis&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP&gt;180mmHg, or diastolic BP&gt;100mmHg)&#xD;
&#xD;
          -  Sensory alteration or paresthesia interfering with function&#xD;
&#xD;
          -  Large quantity of pleural, abdominal or cardiac effusion&#xD;
&#xD;
          -  Severe comorbidity (renal failure, liver failure, hypertension, etc)&#xD;
&#xD;
          -  Prior radiotherapy for primary and metastases leision&#xD;
&#xD;
          -  Men/women who are unwilling to avoid pregnancy&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Women with a positive pregnancy test&#xD;
&#xD;
          -  History of severe allergy&#xD;
&#xD;
          -  HBsAg positive or active viral hepatitis&#xD;
&#xD;
          -  Administration of blood products/ Granulocyte-Colony Stimulating Factor (G-CSF), and&#xD;
             blood transfusion within 14 days&#xD;
&#xD;
          -  Surgical procedure or such as skin-open biopsy, trauma surgery, or other more&#xD;
             intensive surgery within 28 days&#xD;
&#xD;
          -  Systematic administration of antiplatelet drug or non steroid anti-inflammatory drugs&#xD;
             (NSAIDs)&#xD;
&#xD;
          -  Diathesis of bleeding (history of hemoptysis, including cavitation and/or necrosis in&#xD;
             lung metastasis confirmed by imaging), coagulopathy&#xD;
&#xD;
          -  History of gastrointestinal perforation within 1 year&#xD;
&#xD;
          -  Unhealed traumatic bone fracture&#xD;
&#xD;
          -  Uncontrolled diarrhea&#xD;
&#xD;
          -  History of organ recipient&#xD;
&#xD;
          -  Prior cetuximab/bevacizumab/Irinotecan/Oxaliplatin treatment (Adjuvant therapy by&#xD;
             Oxaliplatin is excluded)&#xD;
&#xD;
          -  Administration of atazanavir sulfate&#xD;
&#xD;
          -  Jaundice&#xD;
&#xD;
          -  Ileus or bowel obstruction&#xD;
&#xD;
          -  Clinical diagnosis of Alzheimer's Disease&#xD;
&#xD;
          -  Insulin dependent diabetes&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Any other cases who are regarded as inadequate for study enrollment by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshifusa Nakajima, MD</last_name>
    <role>Study Director</role>
    <affiliation>Japan Clinical Cancer Research Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masashi Fujii, MD</last_name>
    <phone>+81-3-5579-9882</phone>
    <email>masashi.fujii@gioncology.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sachika Koyama, Ms</last_name>
    <phone>+81-3-5579-9882</phone>
    <email>cc13.dc@jaccro.or.jp</email>
  </overall_contact_backup>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>July 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FOLFOXIRI</keyword>
  <keyword>Bmab</keyword>
  <keyword>Cmab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

